Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the healthcare business, growth in the core 2 products, long-acting injectable products, Voyzact and royalty income, together with the launch of the infusion business in the United States, contributed to results. In the nutraceutical business, all three categories addressing social issues grew. Research and development expenses increased due to higher expenses for products under development.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥630,342 million (YoY +8.2%) |
| Operating profit | ¥126,287 million (YoY +1.5%) |
| Ordinary income | ¥130,226 million (YoY +14.9%) |
| Profit attributable to owners of the parent | ¥98,348 million (YoY +15.7%) |
| Net income per share | ¥186.31 |
| Equity ratio | End of the current fiscal period 73.8 / End of previous period 72.3 |
| Total assets | ¥4,209,195 million |
| Net assets | ¥3,174,033 million |
| Cash flows from operating activities | ¥108,882 million |
| Cash flows from investing activities | ¥-22,396 million |
| Cash flows from financing activities | ¥-84,620 million |
| Cash and cash equivalents at end of period | ¥538,296 million |
| Full-year earnings forecast | Net Sales ¥2,520,000 million (YoY +2.1%) / Business profit ¥355,000 million (YoY -20.4%) / Operating profit ¥360,000 million (YoY -24.9%) / Ordinary income Not disclosed / Profit for the period ¥269,000 million (YoY -26.5%) / Net income ¥265,000 million (YoY -27.0%) |
| Annual Dividend Forecast | ¥140 → ¥140（0.0%） |
| Segment revenue | Medical-related business ¥453,822 million (YoY +8.6%), Nutraceutical business ¥138,935 million (YoY +5.8%), Consumer products business ¥7,924 million (YoY +7.3%), Other Businesses ¥30,498 million (YoY +12.7%) |
| Segment profit | Medical-related business ¥114,307 million (YoY -1.9%), Nutraceutical business ¥15,875 million (YoY +5.6%), Consumer products business ¥5,398 million (YoY +13.0%), Other Businesses ¥2,657 million (YoY +71.0%) |
| Depreciation and amortization | ¥30,371 million |
| Impairment loss | ¥288 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors, securities analysts and members of the press) |
| Issued Shares at Period-End | 542,988,917 shares |
| Treasury Shares at Period-End | 15,682,188 shares |
| Factors Behind Changes in Business Performance | In the healthcare business, growth in the core 2 products, long-acting injectable products, Voyzact and royalty income, together with the launch of the infusion business in the United States, contributed to results. In the nutraceutical business, all three categories addressing social issues grew. Research and development expenses increased due to higher expenses for products under development. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the healthcare business, growth in sales of Rexulti, Lonsurf and Abilify, as well as Voyzact and royalty income, and the launch of the infusion business in the United States contributed to results. In the nutraceutical business, all three categories addressing social issues grew. Business profit and operating profit also increased, mainly because gross profit rose in line with higher revenue.